Taiwanese Journal of Obstetrics and Gynecology
Volume 47, Issue 1 , Pages 66-74 , March 2008

Comparisons of Different Dosages of Gonadotropin-Releasing Hormone (GnRH) Antagonist, Short-acting Form and Single, Half-dose, Long-acting Form of GnRH Agonist During Controlled Ovarian Hyperstimulation and in vitro Fertilization

  • Yao-Yuan Hsieh

      Affiliations

    • Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung, Changhua, Taiwan
    • ,
  • Chi-Chen Chang

      Affiliations

    • Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung, Changhua, Taiwan
    • ,
  • Horng-Der Tsai

      Affiliations

    • Department of Obstetrics and Gynecology, Changhua Christian Hospital, Changhua, Taiwan
    • Corresponding Author InformationCorrespondence to: Dr Horng-Der Tsai, Department of Obstetrics and Gynecology, Changhua Christian Hospital, Changhua, Taiwan

,Accepted 15 November 2007.

References 

  1. Testart J , Lefevre B , Gougeon A . Effects of gonadotrophinreleasing hormone agonists (GnRHa) on follicle and oocyte quality . Hum Reprod . 1993;8:511–518
  2. Tapanainen J, Hovatta O, Juntunen K, Martikainen H, Ratsula K, Tulppala M, et al. Subcutaneous goserelin versus intranasal buserelin for pituitary down-regulation in patients undergoing IVF: a randomized comparative study . Hum Reprod . 1993;8:2052–2055
  3. Devreker F , Govaerts I , Bertrand E , Van den Bergh M , Gervy C , Englert Y . The long-acting gonadotropin-releasing hormone analogues impaired the implantation rate . Fertil Steril . 1996;65:122–126
  4. Hsieh Y , Tsai H , Chang C , Lo H . Comparison of a single half-dose, long-acting form of gonadotropin-releasing hormone analog (GnRH-a) and a short-acting form of GnRH-a for pituitary suppression in a controlled ovarian hyperstimulation program . Fertil Steril . 2000;73:817–820
  5. Hazout A , de Ziegler D , Cornel C , Fernandez H , Lelaidier C , Frydman R . Comparison of short 7-day and prolonged treatment with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation . Fertil Steril . 1993;59:596–600
  6. Olivennes F , Fanchin R , Bouchard P , Taieb J , Frydman R . Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist . Fertil Steril . 1996;66:151–153
  7. Diedrich K , Diedrich C , Santos E , et al.   Suppression of the endogenous luteinizing hormone surge by the gonadotrophinreleasing hormone antagonist Cetrorelix during ovarian stimulation . Hum Reprod . 1994;9:788–791
  8. Felberbaum R , Reissmann T , Kupker W , et al.   Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages . J Assist Reprod Genet . 1996;13:216–222
  9. Borm G , Mannaerts B . The European Orgalutran Study Group. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial . Hum Reprod . 2000;15:1490–1498
  10. Albano C , Smitz J , Camus M , Riethmuller-Winzen H , Van Steirteghem A , Devroey P . Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation . Fertil Steril . 1997;67:917–922
  11. Albano C , Smitz J , Tournaye H , Riethmuller-Winzen H , Van Steirteghem A , Devroey P . Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles . Hum Reprod . 1999;14:1426–1430
  12. Hwang JL , Seow KM , Lin YH , et al.   Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study . Hum Reprod . 2004;19:1993–2000
  13. Lee TH , Wu MY , Chen HF , Chen MJ , Ho HN , Yang YS . Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration . Fertil Steril . 2005;83:1700–1707
  14. Itskovitz-Eldor J , Kol S , Mannaerts B , Coelingh Bennink H . First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) . Hum Reprod . 1998;13:294–295
  15. Weghofer A , Margreiter M , Bassim S , Sevelda U , Beilhack E , Feichtinger W . Minimal stimulation using recombinant follicle-stimulating hormone and a gonadotropin-releasing hormone antagonist in women of advanced age . Fertil Steril . 2004;81:1002–1006
  16. Rutherford AJ , Subak-Sharpe RJ , Dawson KJ , Margara RA , Franks S , Winston RML . Improvement of in vitro fertilisation after treatment with buserelin, an agonist of luteinising hormone releasing hormone . Br Med J (Clin Res Ed) . 1988;296:1765–1768
  17. Wasser SK , Sewall G , Soules MR . Psychosocial stress as a cause of infertility . Fertil Steril . 1993;59:685–689
  18. Gianaroli L , Ferraretti AP , Feliciani E , Tabanelli C , Magli C , Fortini D . Prospective randomized study of D-Trp6-LHRH versus buserelin in long desensitization protocols for medically assisted conception cycles . Hum Reprod . 1994;9:220–225
  19. Albuquerque LE , Saconato H , Maciel MC . Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles . Cochrane Database Syst Rev . 2002;(3):CD002808
  20. Porcu E , Dal Prato L , Seracchioli R , Fabbri R , Longhi M , Flamigni C . Comparison between depot and standard release triptoreline in in vitro fertilization: pituitary sensitivity, luteal function, pregnancy outcome, and perinatal results . Fertil Steril . 1994;62:126–132
  21. Dhont M , Onghena A , Coetsier T , De Sutter P . Prospective randomized study of clomiphene citrate and gonadotrophins versus goserelin and gonadotrophins for follicular stimulation in assisted reproduction . Hum Reprod . 1995;10:791–796
  22. Neuspiller F , Levy M , Remohi J , Ruiz A , Simon C , Pellicer A . The use of long- and short-acting forms of gonadotrophinreleasing hormone analogues in women undergoing oocyte donation . Hum Reprod . 1998;13:1148–1151
  23. Dada T , Salha O , Baillie HS , Sharma V . A comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study . Hum Reprod . 1999;14:288–293
  24. Simon A, Benshushan A, Shushan A, Zajicek G, Dorembus D, Lewin A, et al. A comparison between a standard and reduced dose of D-Trp-6-luteinizing hormone-releasing hormone administered after pituitary suppression for in-vitro fertilization . Hum Reprod . 1994;9:1813–1817
  25. Balasch J , Gomez F , Casamitjana R , Carmona F , Rivera F , Vanrell JA . Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot . Hum Reprod . 1992;7:1230–1234
  26. Tsai HD , Chen CM , Lo HY , Chang CC . Subcutaneous low dose leuprolide acetate depot versus leuprolide acetate for women undergoing ovarian stimulation for in-vitro fertilization . Hum Reprod . 1995;10:2909–2912
  27. Shalev E , Leung PC . Gonadotropin-releasing hormone and reproductive medicine . J Obstet Gynaecol Can . 2003;25:98–113
  28. Fujimoto VY , Monroe SE , Nelson LR , Downey D , Jaffe RB . Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (Ganirelix) administered by intranasal spray . Fertil Steril . 1997;67:469–473
  29. Oberye JJ , Mannaerts BM , Huisman JA , Timmer CJ . Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers . Fertil Steril . 1999;72:1006–1012
  30. Plachot M . Biological assessment criteria during antagonist protocols . J Gynecol Obstet Biol Reprod (Paris) . 2004;33:3S32–3S35 [In French]
  31. Felberbaum RE , Diedrich K . Gonadotrophin-releasing hormone antagonists: will they replace the agonists? . Reprod Biomed Online . 2003;6:43–53
  32. Cheung LP, Lam PM, Lok IH, Chiu TT, Yeung SY, Tjer CC, et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial . Hum Reprod . 2005;20:616–621
  33. Roulier R , Chabert-Orsini V , Sitri MC , Barry B , Terriou P . Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3mg) in patients undergoing assisted reproduction treatment . Reprod Biomed Online . 2003;7:185–189
  34. Ng EH , Ho PC . Use of gonadotrophin releasing hormone (GnRH) antagonist (cetrotide) during ovarian stimulation for in-vitro fertilization treatment: multiple doses and single dose . J Obstet Gynaecol Res . 2001;27:261–265
  35. Gordon K , Williams RF , Danforth DR , Hodgen GD . A novel regimen of gonadotropin-releasing hormone (GnRH) antagonist plus pulsatile GnRH: controlled restoration of gonadotropin secretion and ovulation induction . Fertil Steril . 1990;54:1140–1145
  36. Mansour RT , Aboulghar MA , Serour GI , Al-Inany HG , Amin YM , Abou-Setta AM . The use of gonadotropin-releasing hormone antagonist in a flexible protocol: a pilot study . Am J Obstet Gynecol . 2003;189:444–446
  37. Ludwig M , Katalinic A , Diedrich K . Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis . Arch Gynecol Obstet . 2001;265:175–182
  38. Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group . Hum Reprod . 2000;15:526–531
  39. Check ML , Check JH , Choel JK , Davies E , Kiefer D . Effect of antagonists vs agonists on in vitro fertilization outcome . Clin Exp Obstet Gynecol . 2004;31:257–259
  40. Olivennes F , Belaisch-Allart J , Emperaire JC , et al.   Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin) . Fertil Steril . 2000;73:314–320
  41. Fasouliotis SJ , Laufer N , Sabbagh-Ehrlich S , Lewin A , Hurwitz A , Simon A . Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVF . J Assist Reprod Genet . 2003;20:455–460
  42. Zikopoulos K, Kaponis A, Adonakis G, Sotiriadis A, Kalantaridou S, Georgiou I, et al. A prospective randomized study comparing gonadotropin-releasing hormone agonists or gonadotropin-releasing hormone antagonists in couples with unexplained infertility and/or mild oligozoospermia . Fertil Steril . 2005;83:1354–1362
  43. Takahashi K , Mukaida T , Tomiyama T , Goto T , Oka C . GnRH antagonist improved blastocyst quality and pregnancy outcome after multiple failures of IVF/ICSI-ET with a GnRH agonist protocol . J Assist Reprod Genet . 2004;21:317–322
  44. The ganirelix dose-finding study group  . A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon) . Hum Reprod . 1998;13:3023–3031
  45. Fauser BC, Devroey P, Yen SS, Gosden R, Crowley WF, Baird DT, et al. Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks . Hum Reprod . 1999;14:2681–2686
  46. Ludwig M , Felberbaum RE , Devroey P , et al.   Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction . Arch Gynecol Obstet . 2000;264:29–32
  47. Al-Inany H , Aboulghar M . Gonadotrophin-releasing hormone antagonists for assisted conception . Cochrane Database Syst Rev . 2001;(4):CD001750
  48. Vlaisavljevic V , Reljic M , Lovrec VG , Kovacic B . Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles–a prospective, randomized study . Reprod Biomed Online . 2003;7:301–308
  49. Bouchard P , Fauser BC . Gonadotropin-releasing hormone antagonist: new tools vs. old habits . Fertil Steril . 2000;73:18–20
  50. Levi-Setti PE , Cavagna M , Bulletti C . Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH . Eur J Obstet Gynecol Reprod Biol . 2006;126:212–216
  51. Wang C , Hsueh AJ , Erickson GF . LH stimulation of estrogen secretion by cultured rat granulosa cells . Mol Cell Endocrinol . 1981;24:17–28
  52. Escudero E , Bosch E , Crespo J , Simon C , Remohi J , Pellicer A . Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients . Fertil Steril . 2004;81:562–566
  53. Engel JB , Ludwig M , Junge K , Howles CM , Diedrich K . No influence of body weight on pregnancy rate in patients treated with cetrorelix according to the single- and multipledose protocols . Reprod Biomed Online . 2003;6:482–487
  54. Al-Inany H , Aboulghar M . GnRH antagonist in assisted reproduction: a Cochrane review . Hum Reprod . 2002;17:874–885
  55. Hwang JL , Huang LW , Hsieh BC , et al.   Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles . Hum Reprod . 2003;18:45–49
  56. Fauser BC , Devroey P . Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow? . Fertil Steril . 2005;83:1607–1611
  57. Saadat P , Boostanfar R , Slater CC , Tourgeman DE , Stanczyk FZ , Paulson RJ . Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists . Fertil Steril . 2004;82:167–171
  58. Herman A , Raziel A , Strassburger D , Soffer Y , Bukovsky I , Ron-El R . The benefits of mid-luteal addition of human chorionic gonadotrophin in in-vitro fertilization using a downregulation protocol and luteal support with progesterone . Hum Reprod . 1996;11:1552–1557
  59. Felberbaum R , Diedrich K . Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonists . Hum Reprod . 1999;14(Suppl 1):207–221

PII: S1028-4559(08)60057-1

doi: 10.1016/S1028-4559(08)60057-1

Taiwanese Journal of Obstetrics and Gynecology
Volume 47, Issue 1 , Pages 66-74 , March 2008

Article Tools